Case study
Comparison study of anti-cancer drug screening for drug developers (MTAM-HFA) versus current gold standard (Xenograft model)

With MTAM-Screen, highly reliable and translatable data can be obtained at a fraction of the time and cost of conventional means. As evident from this comparison study, the outcome revealed that the MTAM-Screen technique is capable of producing similar outcome to current gold standard; namely, xenografts models

In addition, the time required is only 20% of  and the cost associated with the MTAM-Screen is about 40% of the xenograft models. Furthermore, angiogenesis studies can be conducted without any additional cost and steps; making the MTAM-Screen an excellent solution for your drug development needs